logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The medicine, health, social and economic value

Biomedical innovation cannot be considered an expense, but rather an investment that redounds in the medium and long term in health systems and in society as a whole

For every euro invested in new medicines, the public health system saves between 2 and 7 euros in other health benefits

‘The value of medicine’, a space on the Farmaindustria website, collects updated data on the contributions of new drugs from a global perspective

Source: www.farmaindustria.es

Many people are unaware that for every euro that is invested in new drugs, the public health system can save between 2 and 7 euros in other health services, or that new drugs are directly responsible for up to 73% of the increase in life expectancy. life in developed societies, 70% of the improvement in cancer survival rates and 47% of deaths averted in cardiovascular diseases.

This is the reality shown by scientific evidence, as reflected in the report The value of medicine from a social perspective 2021, carried out by the Weber Foundation with the support of Farmaindustria. The authors of the profuse report -which was presented last March- demonstrate through numerous cases the savings in direct and indirect costs of medicines, their important impact on the results in health and quality of life of people and the contribution that the pharmaceutical industry performs the economies in which it is established.

Therefore, biomedical innovation generates an important social value that must be taken into account by the authorities to contribute to its promotion, and, therefore, the drug cannot be considered an expense, but an investment that results in the medium and long term. term in health systems and in society as a whole. As has been demonstrated during this crude pandemic, the responses to health emergencies are in the new drugs and vaccines, but they are also the best weapon to overcome the deep economic and social crisis caused by SARS-CoV-2.

Beyond the coronavirus, other pathologies have been benefiting from the effect of new drugs. Cancer, HIV, asthma, hepatitis C, multiple sclerosis or rare diseases have stood out in recent years as recipients of important benefits in survival and quality of life.

On the other hand, the industry that makes these advances possible, the pharmaceutical industry, has positioned itself as one of the main sectors that generate added value, quality employment and competitiveness in developed economies. It is a leading R&D sector, with more than 150,000 million euros of annual investment worldwide, an investment that has not stopped growing in the last 25 years. In Spain, 19% of all industrial investment in R&D comes from the pharmaceutical industry.

It is also a source of quality employment: permanent, qualified and diverse. In our country, the pharmaceutical industry directly employs more than 42,000 people, two out of three with higher education and 52% women. And, finally, it is a tractor sector for the economy: each euro in production generates between 1 and 2 additional in other sectors, and each direct job generates up to 4 indirect and induced ones.

All these data and much more can be consulted from today, in an agile and interactive way, on the Farmaindustria website, in the space The value of medicine, which includes a new summary of the main contributions of new drugs from a global perspective.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.